MCAS and POTS: Why These Two Conditions Travel Together
MCAS and POTS: Why These Two Conditions Travel Together
At a Glance
- Mast cell activation syndrome (MCAS) and postural orthostatic tachycardia syndrome (POTS) co-occur at strikingly high rates, with some estimates suggesting over 60% of POTS patients have mast cell dysfunction.
- Mast cell mediators like histamine, prostaglandins, and tryptase directly affect blood vessel tone and heart rate, creating a biochemical bridge between the two conditions.
- Both conditions frequently overlap with Ehlers-Danlos syndrome (EDS), forming a triad that researchers increasingly recognize as a single clinical phenotype.
- Treating one condition without addressing the other often leads to incomplete symptom relief.
- Coordinated treatment targeting mast cell stabilization, autonomic support, and connective tissue management yields the best outcomes.
You have been diagnosed with POTS. You manage the tachycardia, the lightheadedness, the salt loading, and the compression garments. But certain symptoms do not fit neatly into the POTS box: flushing episodes that come out of nowhere, GI symptoms that shift daily, hives after a hot shower, brain fog that persists regardless of hydration status. Your autonomic neurologist says those are not POTS symptoms. Your allergist says you do not have traditional allergies. And yet the symptoms are very real.
If you are nodding along, there is a strong chance that mast cell activation syndrome is running alongside your POTS and has not yet been identified. The overlap between these two conditions is far more common than most patients realize, and understanding why they travel together changes the treatment equation.
The Connection: How Mast Cells Affect the Autonomic Nervous System
Mast cells are immune sentinel cells distributed throughout your body, with especially high concentrations around blood vessels, in the gut lining, and in the skin. When they activate (degranulate), they release a cocktail of chemical mediators including histamine, prostaglandins, leukotrienes, tryptase, heparin, and various cytokines. Under normal conditions, this release is tightly controlled and serves protective functions. In MCAS, the activation threshold drops, and mast cells begin releasing mediators in response to stimuli that should not trigger them.
Several of these mediators have direct effects on the cardiovascular and autonomic systems:
- Histamine causes vasodilation (widening of blood vessels), which drops blood pressure and triggers a compensatory increase in heart rate. This mimics or worsens the orthostatic intolerance seen in POTS.
- Prostaglandin D2 is a potent vasodilator that can cause flushing, hypotension, and tachycardia.
- Tryptase at elevated levels can activate protease-activated receptors on blood vessel walls, influencing vascular permeability and tone.
- Heparin released from mast cells can affect blood coagulation and vascular function.
- Leukotrienes promote bronchoconstriction and can contribute to the air hunger some POTS patients experience.
The net result: when mast cells degranulate, they can produce acute episodes of vasodilation, blood pressure drops, and reflex tachycardia that look exactly like a POTS flare. For many patients, what gets labeled as a “POTS episode” is actually a mast cell-mediated event, or a combination of both processes feeding each other in a vicious cycle.
How Common Is the Overlap?
The co-occurrence of MCAS and POTS is well documented, though exact numbers depend on the diagnostic criteria used and the population studied.
A 2019 study published in the Journal of Allergy and Clinical Immunology found that patients with POTS had significantly higher rates of mast cell mediator elevation compared to healthy controls. Other clinical series have reported that 30 to 65% of POTS patients meet criteria for MCAS when systematically evaluated. Some mast cell specialists believe the true overlap is even higher, because mast cell mediator testing is notoriously unreliable due to strict handling requirements for blood and urine samples.
The connection runs in both directions. Not only do many POTS patients have undiagnosed MCAS, but many MCAS patients develop autonomic dysfunction that meets POTS criteria. This bidirectional relationship suggests shared underlying mechanisms rather than a coincidental association.
The Triad: MCAS, POTS, and EDS
Clinicians who work with these patient populations have long noticed a three-way overlap between MCAS, POTS, and hypermobile Ehlers-Danlos syndrome (hEDS). This triad appears so frequently that some researchers now view it as a distinct clinical phenotype rather than three separate conditions that happen to coexist.
Why These Three Conditions Cluster
The working hypothesis connects all three through connective tissue dysfunction:
- EDS involves defective collagen and connective tissue, which provides the structural framework for blood vessels, the gut, and the tissues where mast cells reside.
- Lax, stretchy blood vessels (from faulty connective tissue) pool blood in the lower extremities upon standing, triggering the heart rate compensations that define POTS.
- Abnormal connective tissue may also alter the extracellular matrix surrounding mast cells, changing their activation threshold and contributing to MCAS.
- Additionally, mechanical stress on lax tissues may directly stimulate mast cell degranulation through mechanoreceptor pathways.
This triad model has practical implications. If you have been diagnosed with one of these three conditions, proactive screening for the other two can prevent years of unnecessary diagnostic wandering.
Diagnostic Challenges: Where Symptoms Overlap
Disentangling MCAS symptoms from POTS symptoms is one of the most challenging aspects of managing both conditions. The following table highlights common symptoms and which condition (or both) may be responsible.
| Symptom | MCAS | POTS | Both |
|---|---|---|---|
| Tachycardia on standing | Yes | Mast cell mediators can worsen | |
| Flushing | Yes | Sometimes | Mast cells often the driver |
| GI symptoms (nausea, cramping, diarrhea) | Yes | Yes | Both pathways contribute |
| Brain fog | Yes | Yes | Cerebral hypoperfusion + neuroinflammation |
| Hives or dermatographia | Yes | No | Mast cell-driven |
| Exercise intolerance | Yes | Yes | Both contribute; heat from exercise can trigger mast cells |
| Lightheadedness | Yes (via vasodilation) | Yes (via blood pooling) | Overlapping mechanisms |
| Fatigue | Yes | Yes | Multifactorial |
| Shortness of breath | Yes (bronchoconstriction) | Yes (deconditioning) | Different mechanisms, similar sensation |
The pattern to watch for: if your POTS symptoms are episodic and unpredictable rather than purely positional, if you have symptoms that worsen with heat, stress, or certain foods, or if standard POTS treatments (salt, fluids, compression) help some symptoms but leave others untouched, MCAS should be on the differential.
Getting Properly Diagnosed
Diagnosis of POTS is relatively straightforward: a sustained heart rate increase of 30 beats per minute or more (40 bpm in adolescents) within 10 minutes of standing, in the absence of orthostatic hypotension, with symptoms present for at least three months. A tilt table test or active standing test confirms the diagnosis.
MCAS diagnosis is more complex. The current consensus criteria require:
- Recurrent episodes of symptoms consistent with mast cell mediator release affecting two or more organ systems
- Objective evidence of mast cell mediator elevation (such as serum tryptase, 24-hour urinary histamine metabolites, prostaglandin D2, or urinary leukotriene E4)
- Response to mast cell-directed therapy (antihistamines, mast cell stabilizers)
The challenge with criterion two is that mediator levels are often normal between flares, and samples must be collected during or shortly after a symptomatic episode with meticulous handling (chilled, processed rapidly). False negatives are extremely common, which is why many experienced clinicians will trial mast cell-directed therapy even when lab work is inconclusive.
Treatment: A Coordinated Approach
When MCAS and POTS coexist, treating one without addressing the other is like patching one tire on a car that has two flats. Coordinated treatment targeting both conditions simultaneously produces far better results.
Mast Cell Stabilization
- H1 antihistamines: Cetirizine (Zyrtec) or fexofenadine (Allegra), often at higher-than-standard doses under medical supervision
- H2 antihistamines: Famotidine (Pepcid) to address GI symptoms and reduce gastric acid overproduction from histamine
- Mast cell stabilizers: Cromolyn sodium (oral, for GI symptoms) and ketotifen (oral, for systemic mast cell stabilization). Ketotifen has both antihistamine and mast cell-stabilizing properties.
- Quercetin: A flavonoid with mast cell-stabilizing properties. Typical dose: 500 to 1,000 mg twice daily.
- Low-dose aspirin: Blocks prostaglandin production from mast cells. Useful for flushing and some cardiovascular symptoms.
Autonomic Support (POTS-Directed)
- Volume expansion: Increased salt intake (3 to 10 grams daily), increased fluid intake (2 to 3 liters daily), and in some cases IV saline infusions
- Compression garments: Waist-high compression stockings (30 to 40 mmHg) and abdominal binders reduce venous blood pooling
- Medications: Fludrocortisone (volume expansion), midodrine (vasoconstriction), propranolol or ivabradine (heart rate control)
- Exercise: Recumbent exercise programs (rowing, recumbent cycling, swimming) gradually build cardiovascular conditioning. The Levine/CHOP protocol is the most studied approach.
Treating the Overlap
Some interventions help both conditions simultaneously. Low-dose naltrexone (LDN) has immune-modulating properties that may stabilize mast cells while also supporting autonomic function. A low-histamine diet reduces the dietary histamine load that can trigger both mast cell and autonomic symptoms. Stress management techniques (vagal toning exercises, paced breathing, meditation) improve autonomic balance and may reduce mast cell reactivity.
Trigger avoidance is also a dual-purpose strategy. Many POTS triggers (heat, prolonged standing, dehydration) are also MCAS triggers. Identifying and managing personal triggers reduces flare frequency from both conditions.
Finding the Right Care Team
Managing MCAS and POTS together requires a care team that understands both conditions. An ideal team might include an immunologist or allergist with MCAS experience, an autonomic neurologist or cardiologist for POTS management, and a primary care provider willing to coordinate between specialists. Functional medicine practitioners with experience in complex, multi-system conditions can also serve as valuable coordinators.
The most important quality in a provider is willingness to treat the whole clinical picture rather than focusing on one diagnosis at a time. Patients with both MCAS and POTS often describe feeling like they are being treated by doctors who each see only a piece of the puzzle. A provider who recognizes the relationship between these conditions can save you years of fragmented care.
